TetraLogic Pharma (TLOG) – Press Releases
-
WaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm Oncology
-
Medivir Completes Previously Announced Oncology Programs Acquisition
-
TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
-
Medivir Strengthens Its Clinical Pipeline by Entering into Agreement to Acquire a Portfolio of Clinical Stage Oncology Programs
-
TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock
-
TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs
-
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual American Society of Hematology Annual Meeting
-
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
-
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
-
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
-
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
-
TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update
-
TetraLogic to Present at the Jefferies 2015 Hepatitis B Summit
-
TetraLogic to Present at the Jefferies 2015 Hepatitis B Summit
-
TetraLogic Provides Update on Hepatitis B Clinical Program
-
TetraLogic Provides Update on Hepatitis B Clinical Program
-
TetraLogic Announces Update on MDS Clinical Program
-
TetraLogic Announces Update on MDS Clinical Program
-
TetraLogic Announces Termination of Public Offering
-
TetraLogic Announces Temporary Halt of Chronic Hepatitis B Trial
-
TetraLogic Announces Pricing of $25 Million Public Offering
-
TetraLogic Announces Pricing of $25 Million Public Offering
-
TetraLogic Announces Public Offering of Common Stock
-
TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B
-
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors
-
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
-
TetraLogic to Present at the 14th Annual Needham Healthcare Conference
-
TetraLogic to Present at the 14th Annual Needham Healthcare Conference
-
TetraLogic Reports 2014 Financial Results and Provides Clinical Programs Update
-
TetraLogic Provides Update on Ovarian Cancer Study
-
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting
-
TetraLogic to Participate in Two Conferences in December
-
TetraLogic Pharmaceuticals Announces Appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as New Directors
-
TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses
-
TetraLogic Announces Closing of $47 Million Convertible Senior Notes Offering
-
TetraLogic Pharmaceuticals Announces Conference Call With Dr. Marc Pellegrini of the Walter and Eliza Hall Institute of Medical Research to Discuss TetraLogic Infectious Disease Program
-
TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious Disease
-
TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting
-
TetraLogic Pharmaceuticals Announces Selection of Phase 2 Dose for Randomized Clinical Study of Birinapant in Combination With Azacitidine in Naive Patients With Higher Risk Myelodysplastic Syndromes
-
TetraLogic to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference
-
TetraLogic to Present at the Deutsche Bank 39th Annual Healthcare Conference
-
TetraLogic Pharmaceuticals Announces Publication of Structural Characterization of Birinapant
-
TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.
-
TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
-
TetraLogic to Present at the Cowen and Company 34th Annual Health Care Conference
-
TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research
-
TetraLogic Announces Exercise of Over-Allotment Option
-
TetraLogic Pharmaceuticals Corporation [TLOG] to Ring The NASDAQ Stock Market Opening Bell
-
TetraLogic Announces Closing of Initial Public Offering of Common Stock
Back to TLOG Stock Lookup